Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MMRV · 1 trial · 4 indications
Sera were tested for VZV Immunoglobulin (IgG) antibody levels by a glycoprotein enzyme-linked immunosorbent assay (gpELISA)
Sera were tested for measles virus IgG antibody levels by an ELISA
Sera were tested for mumps virus IgG antibody levels by an enzyme-linked immunosorbent assay (ELISA)
Sera were tested for rubella virus IgG antibody levels by an ELISA
Sera were tested for VZV IgG antibody levels by gpELISA
Sera were tested for measles virus IgG antibody levels by ELISA
Sera were tested for mumps virus IgG antibody levels by ELISA
Sera were tested for rubella virus IgG antibody levels by ELISA
| Arm | Type | Description |
|---|---|---|
| MMRV (AMP) | EXPERIMENTAL | Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP) |
| MMRV (2006 process) | ACTIVE_COMPARATOR | Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process |
| Name | Type | Description |
|---|---|---|
| MMRV (AMP) | BIOLOGICAL | Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections. |
| MMRV (2006 process) | BIOLOGICAL | Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections. |
Inclusion Criteria: * Negative clinical history for measles, mumps, rubella, varicella, and zoster Exclusion Criteria: * Received any measles, mumps, rubella, or varicella vaccine, either alone or in any combination at any time prior to the study, or is anticipated to receive any of these vaccine...
MMRV is an investigational vaccine being studied for the prevention of measles, mumps, rubella, and varicella. It is currently in Phase 3 clinical development for these infectious diseases, with a focus on measles as a primary indication.
MMRV is being developed by Merck & Company, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
MMRV is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the vaccine remains under investigation for its intended use.
MMRV has one completed Phase 3 clinical trial, identified as NCT01536405. This study evaluated the safety, tolerability, and immunogenicity of the MMRV vaccine made with an alternative manufacturing process, enrolling 1,412 participants aged 12 months and older.
MMRV is a monoclonal antibody designed to target infectious disease pathogens. As a vaccine, it is intended to stimulate an immune response against measles, mumps, rubella, and varicella viruses, although the specific molecular target has not been disclosed.